Lupin Ltd’s fundamental analysis highlights key financial metrics, including a market capitalization of ₹99,386 crore, a PE ratio of 44.0, a debt-to-equity ratio of 0.20 and a return on equity (ROE) of 14.1%. These figures indicate the bank’s financial health and its ability to manage debt while delivering returns.
Lupin Ltd Overview
Lupin Ltd is a leading global pharmaceutical company, established in 1968, specializing in generics, complex generics and biosimilars. With a strong commitment to innovation and quality, it operates in over 100 countries, aiming to enhance patient health outcomes worldwide.
The company has a market capitalization of ₹99,386 crore and is listed on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE). Currently, the stock is trading 5.76% below its 52-week high and 99.6% above its 52-week low.
Lupin Ltd Financial Results
Lupin Ltd’s financial results for FY24 show significant improvement, with sales reaching ₹20,011 crore compared to ₹16,405 crore in FY22. Net profit also surged to ₹1,936 crore from a loss of ₹1,509 crore in FY22.
- Revenue Trend: Lupin’s revenue increased from ₹16,405 crore in FY22 to ₹16,642 crore in FY23, and further to ₹20,011 crore in FY24, reflecting strong growth and market demand for its products.
- Equity and Liabilities: Equity capital stood at ₹91 Crores in FY24, with reserves increasing to ₹14,199 Crores. Total liabilities increased to ₹23,751 Crores in FY24 from ₹22,800 Crores in FY23, indicating a growing financial base.
- Profitability: Operating profit significantly improved from ₹287.22 crore in FY22 to ₹1,798 crore in FY23 and ₹3,811 crore in FY24, demonstrating enhanced operational efficiency and effective cost management.
- Earnings Per Share (EPS): EPS showed remarkable growth, rising from a loss of ₹33.62 in FY22 to ₹9.45 in FY23 and reaching ₹42.01 in FY24, indicating robust profitability and shareholder returns.
- Return on Net Worth (RoNW): The Return on Net Worth (RoNW) slightly increased to 14.1% in FY24 from 14% in FY23, suggesting a modest improvement in returns on shareholders’ equity.
- Financial Position: Lupin’s financial position has strengthened, highlighted by a net profit turnaround from a loss of ₹1,509 crore in FY22 to profits of ₹447.69 crore in FY23 and ₹1,936 crore in FY24, ensuring stability and growth.
Lupin Ltd Financial Analysis
| FY24 | FY23 | FY22 | |
| Sales | 20,011 | 16,642 | 16,405 |
| Expenses | 16,200 | 14,844 | 16,118 |
| Operating Profit | 3,811 | 1,798 | 287.22 |
| OPM % | 18.93 | 10.76 | 1.74 |
| Other Income | 120.17 | 73.36 | 141.69 |
| EBITDA | 3,931 | 1,871 | 428.91 |
| Interest | 311.61 | 274.3 | 142.77 |
| Depreciation | 1,197 | 880.69 | 1,659 |
| Profit Before Tax | 2,422 | 716.49 | -1,373 |
| Tax % | 20.09 | 37.52 | -9.99 |
| Net Profit | 1,936 | 447.69 | -1,509 |
| EPS | 42.01 | 9.45 | -33.62 |
| Dividend Payout % | 19.04 | 42.33 | -11.9 |
All values in ₹ Crores
Lupin Limited Company Metrics
Lupin Ltd has a market capitalization of ₹99,386 crore, with a current stock price of ₹2,179. The company demonstrates strong financial metrics, including an EPS of ₹49.7 and a return on equity of 14.1%.
- Market Cap: Lupin Ltd’s market capitalization stands at ₹99,386 crore, reflecting its status as a leading player in the pharmaceutical industry.
- Book Value: The book value per share is ₹314, indicating the company’s net asset value. A higher book value suggests strong financial health and an ability to generate shareholder value through retained earnings and investments.
- Face Value: Lupin’s face value is ₹2.00, representing the nominal value of each share. This low face value allows for greater flexibility in share issuance and capital raising without significantly impacting the overall equity structure.
- Turnover: Lupin Ltd has an asset turnover ratio of 0.86, indicating efficient use of assets to generate revenue.
- PE Ratio: With a price-to-earnings (PE) ratio of 44.0, Lupin’s shares are priced at a premium compared to earnings. This high valuation reflects investor expectations for future growth and profitability in the pharmaceutical market.
- Debt: Lupin’s total debt is ₹2,922 crore, which coupled with a debt-to-equity ratio of 0.20, suggests a conservative approach to leverage.
- ROE: The return on equity (ROE) for Lupin Ltd is 14.1%, illustrating effective management in generating profits from shareholder equity.
- EBITDA Margin: Lupin’s operating profit margin (OPM) stands at 20.2%, reflecting its operational efficiency and profitability.
- Dividend Yield: Lupin Ltd has a dividend yield of 0.37%, providing a modest return on investment for shareholders. This yield reflects the company’s commitment to returning profits to investors.
Lupin Ltd Stock Performance
The table highlights Lupin Ltd’s impressive return on investment, showing a 24% gain over five years, 34% over three years, and a remarkable 94% return in the past year, reflecting strong performance and investor confidence.
| Period | Return on Investment (%) |
| 5 Years | 24% |
| 3 Years | 34% |
| 1 Year | 94% |
Example:
- A ₹1,00,000 investment yielded ₹1,01,240 after five years.
- A ₹1,00,000 investment grew to ₹1,01,340 in three years.
- A ₹1,00,000 investment reached ₹1,01,940 in just one year.
Lupin Limited Peer Comparison
The competitor analysis of Lupin Ltd reveals a market capitalization of ₹99,385.62 crore, positioning it among notable peers like Sun Pharma (₹443,253.27 crore) and Cipla (₹134,342.82 crore). Lupin demonstrates competitive growth with significant one-year returns of 93.55%.
| S.No. | Name | CMP Rs. | Mar Cap Rs.Cr. | PEG | 3M return % | 1Y return % |
| 1 | Sun Pharma Industries | 1847.4 | 443253.27 | 1.8 | 25.13 | 59.22 |
| 2 | Cipla | 1663.55 | 134342.82 | 1.2 | 7.14 | 33.23 |
| 3 | Dr Reddy’s Labs | 6576.75 | 109746.19 | 0.81 | 9.25 | 16.97 |
| 4 | Zydus Lifesci. | 1051.95 | 105850.71 | 1.53 | -0.47 | 72.86 |
| 5 | Lupin | 2178.85 | 99385.62 | 2.09 | 42.53 | 93.55 |
| 6 | Mankind Pharma | 2400 | 96154.58 | 1.88 | 10.58 | 40.26 |
| 7 | Aurobindo Pharma | 1526 | 89414.28 | 4.09 | 24.01 | 72.94 |
Lupin Limited Shareholding Pattern
The shareholding pattern of Lupin Ltd indicates a stable distribution of ownership. Promoters hold 46.98%, while foreign institutional investors (FII) account for 19.32%. Domestic institutional investors (DII) represent 26.77% and retail investors hold 6.93%, showcasing diverse investor confidence.
| Jun 2024 | Mar 2024 | Dec 2023 | |
| Promoters | 46.98 | 47.01 | 47.04 |
| FII | 19.32 | 18.29 | 16.11 |
| DII | 26.77 | 27.76 | 29.72 |
| Retail & others | 6.93 | 6.94 | 7.11 |
All values in %
Lupin Ltd History
Lupin Ltd was founded in 1968 by Dr. Desh Bandhu Gupta in Mumbai, marking the beginning of its mission to harness science for improved health outcomes. The company’s journey reflects a commitment to innovation and quality in healthcare.
Over the years, Lupin has evolved from its humble origins into a global healthcare leader, expanding its reach across six continents. The company employs over 20,000 individuals, ensuring the delivery of affordable and high-quality medicines to patients in more than 100 countries.
Lupin’s strong focus on research and development has positioned it at the forefront of the pharmaceutical industry. With significant achievements in generics, complex generics, APIs and biosimilars, Lupin continues to enhance its portfolio through scientific innovation and dedication to patient care.
How To Invest In Lupin Limited Share?
Investing in Lupin shares is a straightforward process:
- Open a Demat Account: Start by opening a Demat and trading account with a reliable brokerage firm like Alice Blue.
- Complete KYC: Submit necessary documents for KYC verification.
- Fund Your Account: Deposit funds into your trading account.
- Buy Shares: Search for Lupin shares and place your buy order.
Lupin Limited Fundamental Analysis – FAQs
Lupin Ltd fundamental analysis reveals essential financial metrics: a market capitalization of ₹99,386 crore, a PE ratio of 44.0, a debt-to-equity ratio of 0.20 and a return on equity (ROE) of 14.1%, reflecting solid financial health and effective debt management.
Lupin Ltd has a market capitalization of ₹99,386 crore, representing the total market value of its outstanding shares, highlighting its significant role in the Indian oil drilling and exploration sector.
Lupin Limited is a global healthcare leader founded in 1968, specializing in pharmaceuticals. It focuses on producing affordable, high-quality medicines, including generics, complex generics, and biosimilars and operates in over 100 countries, emphasizing innovation and patient care.
Lupin Limited is owned primarily by its founding family, with Vinita Gupta serving as CEO and Nilesh D. Gupta as Managing Director. The company also has institutional and retail investors holding shares, contributing to its diverse ownership structure.
The main shareholders of Lupin Ltd include the founding Gupta family, with significant stakes held by Vinita Gupta and Nilesh D. Gupta. Additionally, institutional investors, mutual funds and retail shareholders contribute to the company’s diverse ownership landscape.
Lupin Limited operates in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of a wide range of medicines. Its portfolio includes generics, complex generics, biosimilars and active pharmaceutical ingredients (APIs), serving global healthcare needs.
To invest in Lupin Ltd shares, open a trading account with Alice Blue, conduct research on the company’s performance and place a buy order through the broker’s platform. Ensure to monitor your investment and stay updated on market trends.
Determining if Lupin is overvalued or undervalued requires analyzing its current market price compared to its intrinsic value, considering factors like PE ratio, growth prospects and industry comparisons. With a PE ratio of 44.0, Lupin might be fairly valued, reflecting market expectations and moderate growth potential.
We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.
Disclaimer: The above article is written for educational purposes and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
